AMCP CEO Blog: As managed care pharmacy professionals, we work to improve the lives of millions of people. But we also must never forget that behind these large numbers are individual patients.
The Academy of Managed Care Pharmacy (AMCP) thanks Congress for its dedication to combatting the opioid epidemic. The importance of H.R. 6 increases as the number of preliminary CDC reported overdose deaths rise (72,000 overdose deaths in 2017). Both pieces of legislation passed by the House and Senate will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and increase education initiatives for patients and providers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Facilitating Competition and Innovation in the Biological Products Marketplace; Public Hearing; Request for Comments” as published in the Federal Register on July 25, 2018.
Thank you for your leadership in combatting the opioid epidemic. The undersigned organizations represent a diverse group of stakeholders across the health care spectrum committed to aligning 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
AMCP supports the concept of collaborative drug therapy management (CDTM), a formal partnership between a pharmacist and a prescriber that allows the pharmacist to manage a patient’s drug therapy. CDTM, also referred to as collaborative practice, allows pharmacists to use their unique skills and abilities to complement other types of care provided by collaborating professionals to optimize patient outcomes.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Patient-Focused Drug Development on Chronic Pain; Public Meeting; Request for Comments” as published in the Federal Register on July 11, 2018.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to the Centers for Medicare and Medicaid Services’ (CMS’) proposed Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2019; Medicare Shared Savings Program Requirements; Quality Payment Program; and Medicaid Promoting Interoperability Program (CMS-1693-P).
Press Release: AMCP Urges FDA to Issue Final Guidance on Biosimilar Interchangeability Standards and Provide Education on Substituting Interchangeable Products